Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 81

Results For "ED"

8078 News Found

AskBio announces first patient randomized in Phase 1 Trial of AB-1005
News | November 20, 2023

AskBio announces first patient randomized in Phase 1 Trial of AB-1005

Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels


Dr. Reddy's rolls out drug-free non-invasive migraine management device ‘Nerivio’ in India
News | November 17, 2023

Dr. Reddy's rolls out drug-free non-invasive migraine management device ‘Nerivio’ in India

Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain


FDA approves Merck’s Keytruda plus chemotherapy as first line treatment for locally advanced Metastatic HER2-Negative Gastric
Drug Approval | November 17, 2023

FDA approves Merck’s Keytruda plus chemotherapy as first line treatment for locally advanced Metastatic HER2-Negative Gastric

Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone


Pfizer and Astellas' XTANDI approved by USFDA in earlier prostate cancer treatment setting
Drug Approval | November 17, 2023

Pfizer and Astellas' XTANDI approved by USFDA in earlier prostate cancer treatment setting

XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer


Imfinzi plus chemotherapy approved in China as for metastatic biliary tract cancer
Drug Approval | November 16, 2023

Imfinzi plus chemotherapy approved in China as for metastatic biliary tract cancer

Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient


Wockhardt Q2 FY24 consolidated loss lowers at Rs. 77 Cr
News | November 15, 2023

Wockhardt Q2 FY24 consolidated loss lowers at Rs. 77 Cr

Wockhardt has reported total income of Rs. 777 crores during the period ended September 30, 2023


Natco Pharma posts consolidated Q2F Y24 PAT of Rs. 369 Cr
News | November 15, 2023

Natco Pharma posts consolidated Q2F Y24 PAT of Rs. 369 Cr

Natco Pharma has reported total income of Rs. 1060.8 crores during the period ended September 30, 2023


Solara Active Pharma Sciences posts consolidated Q2 FY2024 loss at Rs. 17.16 Cr
News | November 15, 2023

Solara Active Pharma Sciences posts consolidated Q2 FY2024 loss at Rs. 17.16 Cr

Solara Active Pharma Sciences has reported total income of Rs. 426.42 crores during the period ended September 30, 2023


Marksans Pharma posts Q2 FY24 consolidated PAT at Rs. 82.7 Cr
News | November 13, 2023

Marksans Pharma posts Q2 FY24 consolidated PAT at Rs. 82.7 Cr

US business grew by +12.8% YoY


Intermountain Health files complain against Dr. Reddy’s and others
News | November 10, 2023

Intermountain Health files complain against Dr. Reddy’s and others

Dr. Reddy’s maintains that the allegations against it lack merit and will vigorously defend the litigation